Sulfonamide inhibitors of aspartyl protease

Details Sulfonamide inhibitors of aspartyl protease Sulfonamide inhibitors of aspartyl protease

2005-08-25

2008-09-02

Dentz, Bernard (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S050000, C514S086000, C514S212060, C514S263380, C514S230500, C514S314000, C514S318000, C514S357000, C514S367000, C514S374000, C514S459000, C514S470000, C514S604000

Reexamination Certificate

active

07419967

ABSTRACT:
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods For inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

REFERENCES:
patent: 3743722 (1973-07-01), Mohrs et al.
patent: 4330542 (1982-05-01), Descamps et al.
patent: 4629724 (1986-12-01), Ryono et al.
patent: 5196438 (1993-03-01), Martin et al.
patent: 5354866 (1994-10-01), Kempf et al.
patent: 5622949 (1997-04-01), Talley et al.
patent: 5723490 (1998-03-01), Tung
patent: 5744481 (1998-04-01), Vazquez et al.
patent: 5843946 (1998-12-01), Vazquez et al.
patent: 3542567 (1986-06-01), None
patent: 0 022 118 (1981-01-01), None
patent: 0 181 071 (1986-05-01), None
patent: 0 264 795 (1988-04-01), None
patent: 0 346 847 (1989-12-01), None
patent: 0 364 804 (1990-04-01), None
patent: 0 434 365 (1991-06-01), None
patent: 0 468 641 (1992-01-01), None
patent: 0 486 948 (1992-05-01), None
patent: 0 541 168 (1993-05-01), None
patent: 0 594 540 (1994-04-01), None
patent: 2167759 (1986-06-01), None
patent: 2200115 (1988-07-01), None
patent: 59-46252 (1984-03-01), None
patent: 59-48449 (1984-03-01), None
patent: 61-71830 (1986-04-01), None
patent: WO90/07329 (1990-07-01), None
patent: WO91/00725 (1991-01-01), None
patent: WO91/18866 (1991-12-01), None
patent: WO92/08688 (1992-05-01), None
patent: WO92/08698 (1992-05-01), None
patent: WO92/08699 (1992-05-01), None
patent: WO92/08700 (1992-05-01), None
patent: WO92/08701 (1992-05-01), None
patent: WO92/17176 (1992-10-01), None
patent: WO93/23368 (1993-11-01), None
patent: WO93/23379 (1993-11-01), None
patent: WO93/23388 (1993-11-01), None
patent: WO94/04491 (1994-03-01), None
patent: WO94/04492 (1994-03-01), None
patent: WO94/04493 (1994-03-01), None
patent: WO94/05639 (1994-03-01), None
patent: WO94/10134 (1994-05-01), None
patent: WO94/10136 (1994-05-01), None
patent: WO94/18192 (1994-08-01), None
patent: WO94/19322 (1994-09-01), None
patent: WO95/06030 (1995-03-01), None
patent: WO95/07269 (1995-03-01), None
patent: WO95/09843 (1995-04-01), None
patent: WO95/14016 (1995-05-01), None
patent: WO95/32185 (1995-11-01), None
patent: WO96/33184 (1996-10-01), None
patent: WO96/33187 (1996-10-01), None
patent: WO00/76961 (2000-12-01), None
Thompson et al,Ann. Reports Med. Chem., 36, pp. 247-257 (2001).
Polman et al,BMJ, 321, pp. 490-494 (2000).
Cohen et al,J. Neuroimmun., 98, pp. 29-36 (1999).
Menendez-Arias et al., “Moloney Murine Leukemia Virus Protease: Bacterial Expression and Characterization of the Purified Enzyme,”Virology, 1996, pp. 557-563 (1993).
Berger et al., “Multiple-sclerosis-like illness Occurring with Human Immunodeficiency Virus Infection,”Neurology, 39, pp. 324-329 (1989).
Facchini et al., “Human Immunodeficiency Virus-1 Infection and Multiple Sclerosis-like Illness in a Child,”Pediatr. Neurol., 26, pp. 231-235 (2002).
Banker et al.,Modern Pharmaceuticals, pp. 627-629 (1996).
R. Bone et al., “X-ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2Symmetry”,J. Am. Chem. Soc., 113, pp. 9382-84 (1991).
J.C. Craig et al., “Antiviral Synergy Between Inhibitors of HIV Proteinase and Reverse Transcriptase”,Antiviral Chem. and Chemotherapy, 4(3), pp. 161-66 (1990).
S. Crawford et al., “A Deletion Mutation in the 5' Part of the pol Gene of Moloney Murine Leukemia Virus Blocks Proteolytic Processing of the gag and pol Polyproteins”,J. Virol., 53, pp. 899-907 (1985).
M. Cushman et al., “Development of Methodology for the Synthesis of Stereochemically Pure Pheφ[CH2N]Pro Linkages in HIV Protease Inhibitors”,J. Org. Chem., 56, pp. 4161-67 (1991).
D.S. Dhanoa et al., “The Synthesis of Potent Macrocyclic Renin Inhibitors”,Tetrahedron Lett., 33, pp. 1725-28 (1992).
G.B. Dreyer et al., “Hydroxyethylene Isotere Inhibitors of Human Immunodeficiency Virus-1 Protease: Structure-Activity Analysis Using Enzyme Kinetics, X-ray Crystallography, and Infected T-Cell Assays”,Biochemistry, 31, pp. 6646-59 (1992).
G.A. Flynn et al., “An Acyl-Iminium Ion Cyclization Route to a Novel Conformationally Restricted Dipeptide Mimic: Applications to Angiotensin-Converting Enzyme Inhibition”,J. Am. Chem. Soc., 109, pp. 7914-15 (1989).
G. Fontenot et al., “PCR Amplification of HIV-1 Proteinase Sequences Directly from Lab Isolates Allows Determination of Five Conserved Domains”,Virology, 190, pp. 1-10 (1992).
J. Freskos et al., “(Hydroxyethyl)sulfonamide HIV-1 Protease Inhibitors: Identification of the 2-Methylbenzoyl Moiety at P-2”,Bio.&Med. Chem. Lett., 6, pp. 445-450 (1996).
A. Ghosh et al., “Potent HIV Protease Inhibitors Incorporating High-Affinity P2-Ligands and (R)-(Hydroxyethylamino)sulfonamide isotere”,Bio.&Med. Chem. Lett., 8, pp. 687-690 (1998).
E.E. Gilbert, “Recent Developments in Perperative Sulfonation and Sulfation”,Synthesis, 1969, pp. 3-10 (1969).
A. Goldblum, “Modulation of the Affinity of Aspartic Proteases by the Mutated Residues in Active Site Models”,FEBS, 261, pp. 241-44 (1990).
D. Grobelny et al., “Selective Phosphinate Transition-State Analogue Inhibitors of the Protease of Human Immunodeficiency Virus”,Biochem. Biophys. Res. Commun., 169, pp. 1111-16 (1990).
G.D. Hartman et al., “4-Substituted Thiophene- and Furan-2-sulfonamides as Topical Carbonic Anhydrase Inhibitors”,J. Med. Chem., 35, pp. 3822-31 (1992).
S. J. Hays et al., “Synthesis of cis-4-(Phosphonooxy)-2-piperidinecarboxylic Acid, an N-Methyl-D-aspartate Antagonist”,J. Org. Chem., 56, 4984-4086 (1991).
J.R. Huff, “HIV Protease: A Nove Chemotherapeutic Target for AIDS”,Journal of Medicinal Chemistry, 34(8), pp. 2305-14 (1991).
K.Y. Hui et al., “A Rational Approach in the Search for Potent Inhibitors Against HIV Proteinase”,FASEB, 5, pp. 2606-10 (1991).
Y. Kiso et al., “O→N Intramolecular Acyl Migration'-type Prodrugs of Tripeptide Inhibitors of HIV Protease”,Peptides: Chemistry. Structure and Biology, 61, pp. 157-159 (1996).
N.E. Kohl et al., “Active HIV Protease is Required for Viral Infectivity”,Proc. Natl. Acad. Sci. USA, 85, pp. 4686-90 (1988).
X. Lin et al., “Enzymic Activities of Two-Chain Pepsinogen, Two-Chain Pepsin, and the Amino-Terminal Lobe of Pepsinogen”,J. Biol. Chem., 267(24), pp. 17257-63 (1992).
K.P. Manfredi et al., “Examination of HIV-1 Protease Secondary Structure Specificity Using Conformationally Constrained Inhibitors”,J. Med. Chem., 34, pp. 3395-99 (1991).
G.R. Marshall, “Computer-Aided Drug Design”,Ann. Ref. Pharmacol. Toxlcol., 27, pp. 193-213 (1987).
J.A. Martin, “Recent Advances in the Design of HIV Proteinase Inhibitors”,Antiviral Research, 17, pp. 265-76 (1992).
T.D. Meek et al., “Inhibition of HIV-1 Protease in Infected T-Lymphocytes by Synthetic Peptide Analogues”,Nature, 343, pp. 90-90 (1990).
M. Miller et al., “Structure of Complex of Synthetic HIV-1 Protease with a Substrate-Based Inhibitor at 2.3 Å Resolution”,Science; 246, pp. 1149-52 (1989).
M. Miller et al., “Crystal Structures of a Retroviral Protease Proves Relationship to Aspartic Protease Family”,Nature, 337, pp. 576-79 (1989).
K.H.M. Murthy et al., “The Crystal Structures at 2.2-A Resolution of Hydroxyeth

Affiliated with

Also associated with

Rating

Sulfonamide inhibitors of aspartyl protease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfonamide inhibitors of aspartyl protease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamide inhibitors of aspartyl protease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3984662